Sudden Cardiac Death Caused by Small Vessel Vasculitis After COVID-19 vaccination (BNT162b2 nCov-19); A Case Report
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
We present a case of sudden cardiac death due to cardiac small vessel vasculitis after COVID-19 mRNA vaccination (BNT162b2). The deceased was a 76-years-old woman with diabetes mellitus (DM) and chronic hypertension (HTN), who was suffering from generalized pain for a month after the first dose of vaccination, and she unexpectedly expired. The postmortem examination revealed small vessel vasculitis in the heart, lung and vaccinated site of the left arm. These features were similar to those of a previously reported case of a COVID-19 patient with cardiac endotheliitis and multisystem inflammatory syndrome. Plausible explanation suggests that vaccine-induced immunologic changes and vascular dysfunction due to DM and HTN may contribute to the mechanism of adverse events after vaccination. However, further study of additional cases is needed.
Abstract
We present a case of sudden cardiac death due to cardiac small vessel vasculitis after COVID-19 mRNA vaccination (BNT162b2). The deceased was a 76-years-old woman with diabetes mellitus (DM) and chronic hypertension (HTN), who was suffering from generalized pain for a month after the first dose of vaccination, and she unexpectedly expired. The postmortem examination revealed small vessel vasculitis in the heart, lung and vaccinated site of the left arm. These features were similar to those of a previously reported case of a COVID-19 patient with cardiac endotheliitis and multisystem inflammatory syndrome. Plausible explanation suggests that vaccine-induced immunologic changes and vascular dysfunction due to DM and HTN may contribute to the mechanism of adverse events after vaccination. However, further study of additional cases is needed.
참고문헌 (15)
- Polack FP, "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine", N Engl J Med, 383, pp.2603~2615 (2020)
- Barda N, "Safety of the BNT162b2mRNA Covid-19 vaccine in a nationwide setting", N Engl J Med, 385, pp.1078~1090 (2021)
- Jennette JC, "2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides", Arthritis Rheum, 65, pp.1~11 (2013)
- Bonetto C, "Vasculitis as an adverse event following immunization : systematic literature review", Vaccine, 34, pp.6641~6651 (2016)
- Choi Sangjoon, "Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings", Journal of Korean Medical Science, 36(40), pp.1~7 (2021), 대한의학회[DOI]
- Cohen SR, "Leukocytoclastic vasculitis flare following the COVID-19 vaccine", Int J Dermatol, 60, pp.1032~1033 (2021)
- Bostan E, "New-onset leukocytoclastic vasculitis after COVID-19 vaccine", Int J Dermatol, 60, pp.1305~1306 (2021)
- Tenforde MW, "Multisystem inflammatory syndrome in adults : coming into focus", Chest, 159, pp.471~472 (2021)
- Fox SE, "Cardiac endotheliitis and multisystem inflammatory syndrome after COVID-19", Ann Intern Med, 173, pp.1025~1027 (2020)
- Maccio U, "SARS-CoV-2 leads to a small vessel endotheliitis in the heart", EBioMedicine, 63, pp.103182~ (2021)
- van Duin D, "Diagnostic challenges and opportunities in older adults with infectious diseases", Clin Infect Dis, 54, pp.973~978 (2012)
- Angeli F, "SARS-CoV-2 vaccines : lights and shadows", Eur J Intern Med, 88, pp.1~8 (2021)
- Dai L, "Viral targets for vaccines against COVID-19", Nat Rev Immunol, 21, pp.73~82 (2021)
- Verdecchia P, "The pivotal link between ACE2 deficiency and SARS-CoV-2 infection", Eur J Intern Med, 76, pp.14~20 (2020)
- Gheblawi M, "Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the reninangiotensin system: celebrating the 20th Anniversary of the Discovery of ACE2", Circ Res, 126, pp.1456~1474 (2020)